低氧诱导的miR-210对胰腺癌的影响
Mutian Lian1, Maria Mortoglou1, Pinar Uysal-Onganer1
1Cancer Mechanisms and Biomarkers Research Group, School of Life Sciences, University of Westminster, London W1W 6UW, UK.
Current issues in molecular biology
|December 22, 2023
概括
胰腺癌 (PC) 由于晚期诊断和有限的治疗方法而具有挑战性. 缺氧和microRNA-210 (miR-210) 是PC进展和治疗耐药性的关键因素,提供潜在的诊断和治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 胰腺癌 (PC) 带来了重大的临床挑战,其特点是晚期诊断和不良预后.
- PC的一个关键特征是缺氧瘤微环境,促进侵略性行为和治疗耐药性.
- 低氧诱导因子 (HIF) 是已知的低氧诱导PC变化的调节者.
研究的目的:
- 审查缺氧和microRNA-210 (miR-210) 在胰腺癌进展中的作用.
- 探索将低氧,miR-210和PC发育联系在一起的分子机制.
- 突出针对这些途径的潜在诊断和治疗策略.
主要方法:
- 关于胰腺癌,缺氧和microRNAs的现有研究的文献综述.
- 涉及低氧诱导因子 (HIF) 和miR-210.10的分子机制的分析.
- 关于miR-210对PC相关的细胞过程的影响信息的综合.
主要成果:
- 缺氧是PC的关键因素,驱动侵略性表型和治疗抵抗力.
- 微RNA-210 (miR-210) 是一种由HIF依赖和独立通路调节的中心低氧反应分子.
- miR-210影响血管新生,转移和亡,有助于PC的进展.
结论:
- 了解PC中缺氧和miR-210调节对于开发有效治疗方法至关重要.
- miR-210和缺氧通路代表了胰腺癌中新型治疗干预的潜在目标.
- 在低氧条件下调查miR-210可能会导致改善PC的早期诊断策略.
相关概念视频
01:22MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K